Optimal definition of biological tumor volume using positron emission tomography in an animal model

Ingrid Wu
Johns Hopkins University

Hao Wang
Johns Hopkins University

David Huso
Johns Hopkins University

Richard L. Wahl
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Wu, Ingrid; Wang, Hao; Huso, David; and Wahl, Richard L., "Optimal definition of biological tumor volume using positron emission tomography in an animal model." EJNMMI Research. 5, 58. (2015). https://digitalcommons.wustl.edu/open_access_pubs/4356

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Optimal definition of biological tumor volume using positron emission tomography in an animal model

Ingrid Wu, Hao Wang, David Huso and Richard L. Wahl

Abstract

Background: The goal of the study is to investigate $^{18}$F-fluorodeoxyglucose positron emission tomography ($^{18}$F-FDG-PET)'s ability to delineate the viable portion of a tumor in an animal model using cross-sectional histology as the validation standard.

Methods: Syngeneic mammary tumors were grown in female Lewis rats. Macroscopic histological images of the transverse tumor sections were paired with their corresponding FDG micro-PET slices of the same cranial-caudal location to form 51 pairs of co-registered images. A binary classification system based on four FDG-PET tumor contouring methods was applied to each pair of images: threshold based on (1) percentage of maximum tumor voxel counts ($C_{\text{max}}$), (2) percentage of tumor peak voxel counts ($C_{\text{peak}}$), (3) multiples of liver mean voxel counts ($C_{\text{liver}}$) derived from PERCIST, and (4) an edge-detection-based automated contouring system. The sensitivity, which represented the percentage of viable tumor areas correctly delineated by the gross tumor area (GTA) generated from a particular tumor contouring method, and the ratio (expressed in percentage) of the overestimated areas of a gross tumor area (GTA$_{OE}$)/whole tumor areas on the macroscopic histology (WTA$_{H}$), which represented how much a particular GTA extended into the normal structures surrounding the primary tumor target, were calculated.

Results: The receiver operating characteristic curves of all pairs of FDG-PET images have a mean area under the curve value of 0.934 (CI of 0.911–0.954), for representing how well each contouring method accurately delineated the viable tumor area. FDG-PET single value threshold tumor contouring based on 30 and 35% of tumor $C_{\text{max}}$ or $C_{\text{peak}}$ and $6 \times C_{\text{liver}} + 2 \times SD$ achieved a sensitivity greater than 90% with a GTA$_{OE}$/WTA$_{H}$ ratio less than 10%. Contouring based on 50% of $C_{\text{max}}$ or $C_{\text{peak}}$ had a much lower sensitivity of 67.2–75.6% with a GTA$_{OE}$/WTA$_{H}$ ratio of 1.1–1.7%. Automated edge detection was not reliable in this system.

Conclusions: Single-value-threshold tumor contouring using $^{18}$F-FDG-PET is able to accurately delineate the viable portion of a tumor. 30 and 35% of $C_{\text{max}}$, 30 and 35% of $C_{\text{peak}}$, and $6 \times C_{\text{liver}} + 2 \times SD$ are three appropriate threshold values to delineate viable tumor volume in our animal model. The commonly used threshold value of 50% of $C_{\text{max}}$ or $C_{\text{peak}}$ failed to detect one third of the viable tumor volume in our model.
Background

$^{18}$F-FDG-PET can identify local and disseminated malignant lesions and help separate tumor from surrounding normal tissue. Accurate tumor delineation based on FDG-PET imaging is crucial for PET based radiotherapy planning. A key issue is to determine how to best delineate the tumor/non-tumor margin from FDG-PET images. In general, the contouring methods used in these studies can be grouped into several approaches: “top-down,” “bottom-up,” “source-to-background ratio,” or “edge detection” [1–6].

In a top-down approach, a fixed percentage of the highest tumor standard uptake value (SUV) is applied to the FDG-PET image. Fifty percent of the maximum SUV in the tumor was reported as the best threshold for delineation of non-small cell lung cancer (NSCLC) tumors by Wu et al. [2]. Erdi et al. suggested 42 % of the maximum tumor uptake intensity as a proper contouring value in phantom studies [3]. Using a technique similar to Erdi’s, van Baardwijk et al. obtained a significant correlation between FDG-PET volume and histopathological measurements for 23 NSCLC tumors [4].

In a bottom-up approach, tumor delineation is based on normal tissue or the background SUV. Zasadny et al. used a bottom-up approach in lung cancer, where they selected FDG-PET voxel intensities that were over three times the standard deviation above the intensity of the normal lung background as the target tumor volume [5].

Finally, broadly based on edge detection, several institutions have investigated their own computerized algorithms derived from mathematical models. Hatt et al. have developed a fuzzy locally adaptive Bayesian algorithm to compare maximum diameters of delineated volumes on FDG-PET to a histopathological sample [7].

Some studies have left the decision of how to delineate tumor volume in the hands of radiation oncologists and nuclear medicine physicians, using FDG-PET adjunctively to improve the accuracy of tumor volume determined from CT, especially to separate normal tissues from tumor [8].

Another important issue in PET based radiotherapy planning is to determine whether $^{18}$F-FDG-PET imaging can delineate the viable portion of a heterogeneous tumor from the necrotic portion. The validation standards reported in the literature are too simplified to adequately address this aspect of FDG-PET imaging [6]. In most clinical studies, surgical specimens were used as the “gold standard”, and results derived from the tumor contouring methods were compared to the external dimensions of the surgical specimen. There are two major drawbacks to such a validation standard. First, tumors are usually irregularly shaped, which makes a comparison in dimensions quite coarse. Second, a tumor specimen’s outer dimensions provide no information about the tumor’s internal biological heterogeneity. Tumors of similar dimensions may have different internal distributions of viable tumor tissues, and there are only a few studies taking into account such biological variation [8]. Tumors may shrink during histological processing, which further complicates the overall validation process [9].

The purpose of our study was to design a validation system for FDG-PET tumor contouring method using corresponding cross-sectional pathology based on frozen tumor sections as the gold standard. We also investigated FDG-PET’s ability, using several analytical approaches, to demonstrate a tumor’s internal heterogeneous distribution of viable tumor tissues in addition to delineation of the total tumor volume. We would like to quantify the viable and necrotic regions within a tumor to facilitate animal radiotherapy planning studies seeking dose efficiency and reduction or tumor necrosis targeted radiotherapy [10, 11].

Methods

This project was approved by the animal care committee. IRB approval was not obtained because this was a pre-clinical study and no human subjects or tissues were involved.

Tumor model

Carcinogen-induced rat mammary tumor line was selected as the animal model due to their known heterogeneity and syngeneic nature, allowing them to grow in rodents with a competent immune system [12, 13]. Suspension containing approximately $10^6$ cells was sequentially propagated in vivo by implanting them in the scapular fat pad region of female Lewis rats (purchased from Charles River Laboratories). The animal models in our experiment were established from three consecutive generations of propagations in a total of nine Lewis rats.

Tumor imaging

Rats with mammary tumors were prepared for FDG-PET imaging when the tumors reached at least 3 cm in diameter in about 2–3 weeks. Tumor-bearing rats were shaved in the scapular area and fasted the night before imaging with a Philips MOSAIC Animal PET Imaging System [14]. To maintain identical anatomical orientations during tumor imaging and tumor specimen processing, a stand-alone rat bed was constructed in the same shape as the animal PET scanner imaging bed.

On the day of imaging, tumor-bearing rats were anesthetized with 1 % isoflurane. $3.7 \times 10^7$ Bq (1 m Ci) of $^{18}$F-FDG (P.E.T.Net, Glen Burnie, MD, USA) was injected through a tail vein. After radiotracer injection, the rat was kept warm for a 1-h uptake period until imaging and then placed in the imaging bed in the prone position, sedated, with the tumor on its back positioned upright.
Using the PET scanner’s integrated laser positioning system, 3–5 transverse sectioning positions were identified and marked in each rat. At each sectioning position, the skin over the tumor was marked and the imaging bed position recorded. In order to facilitate accurate translational and rotational imaging registration, two fiducial markers with $^{18}$F-FDG were placed at each transverse sectioning line (Fig. 1a). In order to reconstruct the attenuation corrected FDG-PET images, a transmission scan was performed before the PET scan. The static PET imaging acquisition lasted for 30 min.

The FDG-PET images were reconstructed using three-dimensional row-action maximum-likelihood algorithm on a $128 \times 128 \times 120$ matrix, where the voxel size equals $1 \text{ mm}^3$. Attenuation was corrected using a $^{137}$Cs single photon transmission measurement. Decay correction, normalization, dead time correction, and scatter correction were also utilized [12].

**Tumor processing**

After imaging, the rat was humanely sacrificed in the imaging bed by gas anesthesia overdosing, with its imaging position maintained. It was then carefully transferred to the identical rat bed with its anatomical orientation preserved. The whole rat and its rat bed were quickly frozen using dry ice and transferred to a $-20 \text{ °C}$ freezer. In the following 2–3 h, the whole rat was allowed to freeze to the extent where the necrotic portion of the tumor was solidified but could still be sliced into transverse sections with relative ease.

We had a device specially designed to allow easy and accurate sectioning of the rat along its skin markings, so that the sectioning planes parallel to the axial planes of the FDG-PET images. The tumor-containing portion of each rat was sectioned transversely into three to five blocks, and each sectioning resulted in a rostral and a caudal cross-sectional surfaces. In order to preserve the anatomical configuration, the blocks were sectioned at a sufficient thickness (6–8 mm) to prevent block deformity from the shearing force of sectioning. All blocks were stored in an airtight box to avoid moisture and kept in the freezer overnight (Fig. 1b). All cross-sectional surfaces were imaged at a visible light wavelength and digitized using a flat panel color scanner with a resolution of 200 dots per inch (DPI). These images are the macroscopic histological images of tumor blocks.

Rats 1–8 were processed in the method described above, and a total of 51 technically adequate macroscopic histological images were acquired from eight rats. Rat 9, serving as a reference rat, was processed differently. After it was sacrificed on the imaging bed, we harvested its tumor, submerged the tumor specimen in 10 % formalin, and sent it for hematoxylin and eosin (H&E) staining and microscopic histology.

**Image data processing**

There were two categories of image data to be processed: (1) Macroscopic histological images generated from cross-sectional surfaces of the frozen tumor blocks, as demonstrated in Fig. 1b and Fig. 2a. (2) The reconstructed FDG-PET imaging slices of the same tumor at the identical cranial-caudal level as the histological images from the first category of data, as demonstrated in Fig. 2b.

A note needed to be made on the comparison between the macroscopic histological image and the FDG-PET image. Each FDG-PET slice represented a three-dimensional (3D) distribution of radioactivity. Ideally, the corresponding histological gold standard should have been a very thin piece of 3D tissue block of the same thickness, and the comparison should have been made in volume instead of area. However, to produce a tissue block of 1-mm thickness and measure its viable and necrotic volumes is technically difficult. Instead, we used...
the macroscopic histological image of the tumor’s cross-sectional surface—a two-dimensional (2D) image (as demonstrated in Fig. 2a) with the assumption that there was modest macroscopic variation in the distribution of viable tumor tissues within a 1-mm thickness.

First, a pathologist reviewed the gross tumor tissue blocks in paraffin that was processed from rat 9—the reference rat, to identify and delineate the viable portion of the tumor by its macroscopic morphology, and the delineation was validated using microscopic examination of the associated H&E stains (Fig. 3). Next, the whole tumor area and its viable portion were delineated on each of the 51 macroscopic histological images, without review of the FDG-PET data. Thus, the examination of the unstained frozen sections for the fraction of viable tumor was informed by the detailed examination of the macroscopic and microscopic characteristics of the H&E-stained paraffin-embedded tissues from rat 9.

For each sectioning position, a corresponding cranial-caudal level in the FDG-PET images was determined using imaging bed position, and two FDG-PET slices closest to that level were selected. Then, the rostral FDG-PET slice was matched to the macroscopic histological image of the rostral cross-sectional surface and the caudal PET slice to the histological image of the caudal surface, thus forming two pairs of matched images with each pair containing a FDG-PET slice and its matched macroscopic histological image.

After each pair of matched images was established, the FDG-PET slice was registered to the histological image under the guidance of the fiducial markers using Amide software (http://amide.sourceforge.net/index.html). The macroscopic histological image acquired at 200 DPI had a pixel size of 0.127 × 0.127 mm², which was much smaller than a FDG-PET slice’s axial pixel size of 1 × 1 mm². In order for them to co-register, the smaller pixel size was adjusted to match the larger one, resulting in a coarser histological image with a lower resolution, as demonstrated in Fig. 2c, d.

Analysis of image data

Four FDG-PET tumor contouring methods were investigated. The first three methods were based on fixed single value thresholds (voxel counts in our study), and the last method used an auto-detection algorithm (MIM software, Cleveland, Ohio), which was based on acceleration/deceleration of pixel intensity changes [15].

In method I, a spectrum of thresholds was determined by using 15–90 % (in 5 % increments) of the maximum single tumor voxel counts (C_{max}) in each rat.

In method II, all 3 × 3 × 3 cubic voxel sets containing the C_{max} voxel were examined. Tumor peak counts (C_{peak}) was defined as the highest average voxel counts among all 3 × 3 × 3 cubic voxel sets. A spectrum of thresholds was determined using 15–90 % (in 5 % increments) of C_{peak}.

In method III, a liver mean voxel count (C_{liver mean}) was defined as the average voxel counts in a sphere 6 mm in diameter, located in the right upper portion of the liver of each rat. The standard deviation (SD) of voxel counts in the sphere (C_{liver SD}) was also calculated. A spectrum of thresholds was determined by a range of multiples of C_{liver mean} plus 2 × C_{liver SD}.

In method IV, each rat’s FDG-PET image file was imported to the MIM workstation (Cleveland, OH), and the “PET/SPECT edge contour” function was used to create a 3D tumor contour. The operator had to manually seed the tumor center to start the algorithm.

In methods I–III, in each FDG-PET slice, a gross tumor area (GTA) was generated by all pixels equal to
or above the threshold value. In method IV, a gross tumor volume (GTV) was automatically generated from the contiguous 3D set of edge points defined by MIM software.

In each pair of co-registered FDG-PET slice and its corresponding macroscopic histological image, different GTAs generated from methods I–III were tested against the viable area of the tumor in the corresponding histological image. Statistical calculations were performed using a binary classification system with the assistance of ImageJ (NIH) to assess each GTA’s performance on tumor delineation (http://rsb.info.nih.gov/ij/). The GTV contoured in method IV was analyzed separately.

**Statistical calculations**

We designed a binary classification system to evaluate FDG-PET’s accuracy in contouring the viable and necrotic portions of the tumor on a macroscopic histological image. The test population—the areas to be tested—was the whole tumor areas (including both viable and necrotic portions of the tumor) delineated on the macroscopic histological image by the pathologist (WTAP), in units of pixels (Fig. 4a). The viable area of the tumor was considered as condition positive (validation standard) (Fig. 4c 5 + 6 + 7), and the necrotic area was considered as condition negative (Fig. 4c 1 + 2 + 3 + 4).

In each pair of co-registered images, different gross tumor areas (GTAs) were generated from the FDG-PET slice using methods I–III (Fig. 4b). Each GTA was tested on the histological image separately. The test outcome was positive (viable), if the histological area to be tested was included by the GTA (Fig. 4c 3 + 4 + 5), or negative (necrotic), if the area to be tested was not included by the GTA (Fig. 4c 1 + 2 + 6 + 7). As the test results for each histological area (in units of pixels) may or may not match that area’s actual viability status, true positive was defined as the viable areas of the tumor on the histological image that were correctly identified as viable by the GTA (Fig. 4c 5), and true negative was defined as the necrotic areas of the tumor that were correctly identified as necrotic (Fig. 4c 1 + 2). Sensitivity was defined as the viable areas correctly identified by GTA (true positive)/viable tumor areas delineated on histology (condition positive), and specificity was defined as the necrotic tumor areas correctly identified by GTA (true negative)/the necrotic tumor areas delineated on histology (condition negative). Notably, only the tumor areas on a histological image were tested in the design above. The surrounding normal tissues were excluded from the test population. To further evaluate the accuracy of each GTA, GTA_{OE} was defined as the overestimated areas in the GTA that extended beyond the whole tumor areas on the histological image (WTAP) into the surrounding normal tissue and background air space (Fig. 4c 8 + 9 + 10).

Different GTAs generated from methods I–III were applied to each of the 51 pairs of co-registered images, and the resulting sensitivity, specificity, and GTA_{OE}/WTAP ratio (in percentage) were calculated. A receiver
operating characteristic curve (ROC curve), which illustrated each contouring method's performance on tumor delineation for each pair of co-registered images, was plotted using sensitivity and 1-specificity as x and y axes, respectively, with its area under the curve (AUC) approximated using the Gini coefficient (Fig. 5) [16]. Because in any particular pair of images, the GTAs generated from all three methods were all based on single value threshold (voxel counts) from the same FDG-PET slice, there was only one ROC curve for each image pair. In other words, in any particular pair of images, the ROC curves plotted from each of the three methods overlapped and complimented one another.

The generalized estimating equations (GEE) method was used to estimate the mean and standard error of the measurements, accounting for the correlations of the two cross-sectional surfaces from a single transverse sectioning [17]. Standard error of the mean (SE) and 95% confidence intervals (CIs) were computed based on 10,000 bootstrap samples.

Results and discussion

In methods I–III, the means and 95% CI of the sensitivity, specificity, and GTA\textsubscript{OE}/WTA\textsubscript{H} ratio from 51 pairs of images were calculated for each GTA generated from each contouring method, respectively (Tables 1, 2, and 3). The ROC curves of all pairs of images have a mean AUC of 0.934 (CI of 0.911–0.954). The means and 95% CIs of the sensitivity and GTA\textsubscript{OE}/WTA\textsubscript{H} ratio of GTAs generated from each of the three methods were plotted in Fig. 6a–c, respectively.

In method IV, the resulting GTV using MIM’s “PET edge” function was not reproducible. Depending on the position where the seed point was chosen and the direction it was dragged, the resulting tumor delineations were different (Fig. 6d).

Our study uses immunologically intact rats, which resemble human tumors in vivo. As animal irradiation systems become more common, more precise contouring methods of animal tumors are of experimental importance.

Our study demonstrates that single value threshold tumor contouring method using \textsuperscript{18}F-FDG-PET can reliably delineate the viable portion of a tumor, as illustrated by a mean AUC of 0.934 (CI of 0.911–0.954) (Fig. 5). There is some variation among the eight rats in the sensitivities and specificities calculated from the same threshold percentage using the same contouring method, as illustrated by the confidence intervals in Tables 1, 2,
One common concern during radiotherapy is the possibility of irradiating the normal structures surrounding the primary tumor target. The most desirable contouring method for radiotherapy planning would have a sensitivity (and to a lesser degree, a specificity) close to 100 %, with a \( \text{GTA}_{OE}/\text{WTA}_{H} \) ratio close to 0 %. In our study, a common characteristic demonstrated in Fig. 6 was that as the threshold value of a particular GTA extended into the normal structures surrounding the primary tumor target.

Table 2 Method II—percentage of tumor peak activity

| \( C_{\text{peak}} \) (%) | Sensitivity (CI) | Specificity (CI) | \( \text{GTA}_{OE}/\text{WTA}_{H} \) (CI) |
|---------------------------|------------------|------------------|---------------------------------|
| 15                        | 100.0 % (99.9–100.0 %) | 52.2 % (23.0–42.2 %) | 28.3 % (23.0–33.8 %) |
| 20                        | 99.6 % (99.4–99.8 %) | 46.9 % (36.1–57.4 %) | 18.9 % (15.0–23.0 %) |
| 25                        | 98.7 % (98.1–99.2 %) | 57.4 % (47.2–67.1 %) | 13.3 % (10.3–16.5 %) |
| 30                        | 96.9 % (95.9–97.8 %) | 66.0 % (57.1–74.5 %) | 9.3 % (7.0–11.8 %) |
| 35                        | 93.7 % (92.0–95.3 %) | 73.8 % (65.8–81.1 %) | 6.3 % (4.5–8.3 %) |
| 40                        | 89.0 % (86.4–91.5 %) | 80.2 % (73.2–86.5 %) | 4.2 % (2.8–5.8 %) |
| 45                        | 83.1 % (79.8–86.1 %) | 86.3 % (80.9–91.2 %) | 2.7 % (1.8–3.8 %) |
| 50                        | 75.6 % (72.0–79.1 %) | 90.8 % (86.5–94.6 %) | 1.7 % (1.1–2.5 %) |
| 70                        | 34.1 % (29.5–38.9 %) | 98.9 % (98.0–99.6 %) | 0.1 % (0.0–0.2 %) |
| 90                        | 8.4 % (5.5–11.6 %) | 99.9 % (99.7–99.9 %) | 0.0 % (0.0–0.0 %) |

\( C \) confidence interval, \( \text{GTA}_{OE} \) gross tumor area overestimate, \( \text{WTA}_{H} \) whole tumor areas on histology
contouring using 50% of C_{max} or C_{peak} – commonly reported threshold values in the literature, had relatively low sensitivities of 67.2%–75.6% with very low GTA\_{OE}/WTA\_{H} ratios of 1.1%–1.7%, and may be considered in sub-volume boosting, where a high dose of radiation is prescribed to the most metabolically active region of the tumor.

Successful radiotherapy decreases peak tumor activity, while the liver radioactivity is expected to remain relatively constant [19]. Tumor contouring methods based on liver activity, therefore, potentially could be particularly helpful in post-radiation re-planning situations. Tumor contouring based on PERCIST with 1.5 × C_{liver mean} + 2 × SD had a sensitivity of 100% but a high GTA\_{OE}/WTA\_{H} ratio of 50.5% (CI 42.7–59.1) [20]. Tumor contouring using 6 × C_{liver mean} + 2 × SD had a sensitivity of 95.1% (CI 93.5–96.5) and a GTA\_{OE}/WTA\_{H} ratio of 7.4% (CI 5.6–9.5%), which was comparable to contouring using 30 and 35% of C_{max} or C_{peak}, and may be considered in radiotherapy planning where prior radiation was performed.

Although our study was limited to mammary tumor in an animal model, it provided a template approach to perform similar studies with other tumor types using different radiotracers. As more radiotracers become available, similar studies can be performed to facilitate their application in clinical settings. For example, such an approach could be used in ¹⁸F-fluoromisonidazole(F-MISO)-PET to evaluate how FMISO characterizes tumor tissue hypoxia in vivo in animal model and provide a roadmap for further research on FMISO-based radiotherapy planning [21].

Several issues need to be discussed. The first issue regards the variation between macroscopic and microscopic pathologies. The frankly necrotic portion of a tumor is easy to differentiate macroscopically from the viable portion. However, the gray zone in between, where there is a mixture of tumor cells, immunological cells, and cell debris, is difficult to identify on macroscopic images. To be conservative, we included these areas in the viable portion of the tumor, although the clinical importance of these areas needs further research.

The second issue is related to the limitation of our imaging system. The spatial resolution of the animal micro-PET scanner is approximately 2 mm [12]. With a typical cell diameter at tens of microns, failure to detect small tumors is possible. This limits the accuracy of the data analysis, especially when the tumors are small. Our data analysis is also limited by partial volume effect, which is more prominent in small tumors. Utilizing reconstruction algorithm designed to improve image-space resolution, e.g., resolution modeling during reconstruction, could help to improve the quality of our PET imaging and decrease partial volume effect [22].

The third issue is that tumors vary substantially in their metabolic activities. Our tumor model has relatively high FDG uptake, and the variability in voxel counts may affect the optimal threshold for tumor contouring. In fact, FDG-PET tumor contouring may even be tumor specific, and human tumors may have lower FDG uptake.

Finally, the contouring methods investigated in our study are based on single value threshold. It is worth debating whether tumor volume is best delineated with single value. Our last method using an edge detection technique was an attempt to evaluate the performance of a non-single-value contouring method. However, due to the system’s lack of reproducibility, we were unable to reliably analyze the data. A potential future study is to investigate non-single-value contouring algorithms developed by other groups, compare their results to those obtained in this study, and explore other edge detection methods. In addition, CT-based tumor contouring, which is usually performed in clinical settings, was not investigated for comparison to PET-based contouring methods in our study. This is due to technical difficulty in acquiring an intravenously enhanced CT imaging of a rat while maintaining its anatomical orientation between two different imaging beds. Hybrid small animal PET/CT or PET/MR may provide better soft tissue characterization and additional useful information.

**Conclusions**

Single-value threshold tumor contouring using ¹⁸F-FDG-PET is able to accurately delineate the viable portion of a tumor in this rodent model and provide an imaging blueprint to future animal radiotherapy planning studies.
seeking dose efficiency and reduction. Our study design may also provide a template approach to radiotracer validation in small animals and help to inform future clinical studies. While human tumors no doubt differ, our study suggests threshold values of 30 and 35 % of \( C_{\text{max}} \) or \( C_{\text{peak}} \) and \( 6 \times \text{Cliver} + 2 \times \text{SD} \) are all appropriate for delineating viable tumor volume in a rodent breast cancer model.

Compliance with ethical standards

Ethical approval: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.

Competing interest

Ingrid Wu declares that she has no conflict of interest. Hao Wang declares that she has no conflict of interest. David Huso declares that he has no conflict of interest. Richard Wahl declares that he has no conflict of interest.

Authors’ contributions

IW participated in all parts of the study and manuscript drafting. HW performed the statistical analysis. DH participated in data processing and analysis. RW participated in the conception and design of the study, close supervision of the study, and critical revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Special thanks to John Eng M.D. and Christopher Endres M.D. from the Department of Radiology, James Engles and Judy Buchanan from the Division of Nuclear Medicine, and Mariah Klunk from the Center of Infection and Inflammation Imaging Research.

Funding

This study was funded by NIH grant T-32CA121937.

Author details

1Department of Radiology, Division of Nuclear Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4Division of Oncology Biostatistics and Bioinformatics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3Department of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5Department of Radiology, Washington University School of Medicine, Campus Box 8131, 6605, Euclid Ave, St. Louis, MO 63110, USA.

Received: 24 July 2015 Accepted: 9 October 2015
Published online: 21 October 2015
References

1. Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rübe C, et al. Comparison of different methods for delineation of 18 F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med. 2005;46(8):1342–8.

2. Wu K, Ling YC, Hornby J, Freeman M, Hwang D, Tsao MS et al. PET CT thresholds for radiotherapy target definition in non-small-cell lung cancer: how close are we to the pathologic findings? Int J Radiat Oncol Biol Phys. 2010;77(3):699–706.

3. Erdi YE, Mawlawi O, Larson SM,Imbriaco M, Yeung H, Finn R, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997;80(12 Suppl):2505–9.

4. van Baardwijk A, Bosmans G, Boersma L,Buijsen J, Wanders S, Hochstenbag M, et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys. 2007;68(3):771–8. Epub 2007 Mar 29.

5. Zasadny KR, Kison PV, Francis IR, Wahl RL. FDG-PET determination of metabolically active tumor volume and comparison with CT. Clin Positron Imaging. 1998;12:1.

6. Cheebsumon P, van Velden F HP,Maqsood Yaqub, Corneline J Hoekstra, Linda M Velasquez, et al. Measurement of metabolic tumor volume: static versus dynamic FDG scans. EJNMMI Res. 2011; 1: 35. Published online 2011 Dec 14. doi: 10.1186/2191-219X:1-35.

7. Hatt M, Cheze le Rest C, Descourt P, Dekker A, De Ruyscher D, Oeiwers Met al. Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications. Int J Radiat Oncol Biol Phys. 2010;77(1):301–8.

8. Daine JF, Duprez T, Weynard B, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology. 2004;233(1):93–100. Epub 2004 Aug 18.

9. Effect of formalin fixation on surgical margins in breast cancer surgical specimen. Zaidi M, et al. Int J Breast Cancer. 2014;2014:121838. doi: 10.1155/2014/121838. Epub 2014 Oct 2.

10. Matinfar M, Jodarchia I, Ford E, Wong J, Kazanzides P. Precision radiotherapy for small animal research. Med Image Comput Comput Assist Interv. 2008;11(Pt 2):2619–26.

11. Liu X, Haibo Shao, Jian Zhang, Ziping Sun, Feng Chen, Xu Dai, et al. Tumor necrosis targeted radiotherapy of non-small cell lung cancer using radiolodinated protiohypericin in a mouse model. Oncotarget. 2015;6(16):14247–142595.

12. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of labeled fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med. 1995;36(10):1854–61.

13. Ethier SP, Cundiff KC. Importance of extended growth potential and growth factor independence on in vivo neoplastic potential of primary rat mammary carcinoma cells. Cancer Res. 1987;47(20):5316–22.

14. Huisman MC, Reder S, Weber AW, Ziegler SI, Schwaiger M. Performance evaluation of the Philips MOSAIC small animal PET scanner. Eur J Nucl Med Mol Imaging. 2007;34(4):532–40. Epub 2006 Nov 22.

15. MIM user guide version 5.4

16. Hand DJ, Till RJ. A simple generalization of the area under the ROC curve for multiple classification problems. Machine Learning. 2001;45(2):171–86.

17. Ratcliffe SJ, Shults J. GEEQBOX: a MATLAB toolbox for generalized estimating equations and quasi-least squares. Journal of Statistical Software. 2008;25(14):1–14.

18. MacManus MP, Hicks RJ. Where do we draw the line? Contouring tumors on positron emission tomography/computed tomography. Int J Radiation Oncology Biol Phys. 2008;71(1):2–4.

19. Gritters LS, Wahl RL. Single photon emission computed tomography in cancer imaging. Oncology. 1993;7(7):59–63. 66.

20. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:1125–50S.

21. Imaging modalities to assess oxygen status in glioblastoma. Corroyer-Dulmont, et al. Front. Med. 2015 19 August 15  http://dx.doi.org/10.3389/fmed.2015.00057.

22. Sureau FC et al. Impact of image-space resolution modeling for studies with the high-resolution research tomograph. J Nucl Med. 2008;49(6):1000–8. doi:10.2967/jnumed.107.05351.